Lundbeck

Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in
Pharma Voice
Thu, 11/7/24 - 11:12 am
M&A
Vertex Pharmacuticals
Alpine Immune Sciences
Eli Lilly
Morphic
Novartis
MorphoSys
Mariana Oncology
AstraZeneca
Fusion Pharmaceuticals
Lundbeck
Longboard Pharmaceuticals
AbbVie
Aliada Therapeutics
Lundbeck planning for four novel drugs in phase 3 in 2026
Pharmaphorum
Thu, 10/24/24 - 09:47 am
Lundbeck
R&D
new molecular entity
epilepsy
Lundbeck signs $2.5B check for Longboard, seeing blockbuster potential in epilepsy med
Fierce Biotech
Mon, 10/14/24 - 10:10 am
Longboard Pharmaceuticals
Lundbeck
M&A
epilepsy
bexicaserin
Lundbeck taps Charles River for AI-enabled neuro drug discovery
Fierce Biotech
Wed, 10/2/24 - 10:44 am
Lundbeck
Charles River Labs
drug discovery
artificial intelligence
Abilify Asimtufii campaign uses 3D CGI to detail journey of bipolar I patients
Medical Marketing and Media
Mon, 09/9/24 - 07:14 pm
pharma marketing
DTC advertising
Ability Asimtufii
Otsuka
Lundbeck
Lundbeck ups guidance on higher expectations for Rexulti, Vyepti
First Word Pharma
Tue, 08/20/24 - 11:50 am
Lundbeck
earnings
Rexulti
Vyepti
Lundbeck leaves Trintellix to partner Takeda in the US, opting for royalties as it focuses efforts on Rexulti
Fierce Pharma
Wed, 07/31/24 - 11:16 pm
Lundbeck
Takeda
Trintellix
antidepressants
Rexulti
Otsuka and Lundbeck report data from three PTSD treatment trials
Clinical Trials Arena
Wed, 05/29/24 - 11:52 am
Otsuka
Lundbeck
PTSD
clinical tirals
brexpiprazole-sertraline
3 patent expirations in 2024 and how companies are pivoting
Pharma Voice
Wed, 04/17/24 - 11:13 am
patents
patent cliff
Bayer
J&J
Xarelto
Novo Nordisk
Victoza
Otsuka
Lundbeck
Abilify
Lundbeck CEO eyes deals to bolster pipeline, complement growth drivers ahead of patent losses
Fierce Pharma
Tue, 01/23/24 - 11:08 am
Lundbeck
Charl van Zyl
Pharma CEOs
Vyepti
Rexulti
5 minutes with — Lundbeck CEO Dr. Deborah Dunsire
Pharma Voice
Fri, 08/11/23 - 09:55 am
Lundbeck
Pharma CEOs
Deborah Dunsire
Lundbeck replaces retiring CEO Deborah Dunsire with UCB exec after breaking sales record
Fierce Pharma
Tue, 06/27/23 - 10:17 am
Lundbeck
Pharma CEOs
Deborah Dunshire
Charl van Zyl
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
Yahoo/Benzinga
Thu, 05/11/23 - 08:53 pm
Otsuka
Lundbeck
FDA
Rexulti
Alzheimer's agitation
Otsuka, Lundbeck gain FDA nod for longer-acting version of schizophrenia drug Abilify
Fierce Pharma
Mon, 05/1/23 - 10:04 am
Otsuka
Lundbeck
FDA
Abilify
Asimtufii
bipolar disorder
FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's disease agitation
Fierce Pharma
Sun, 04/16/23 - 11:17 pm
Lundbeck
Otsuka
Rexulti
Alzheimer's disease
FDA
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
Mon, 04/3/23 - 09:41 am
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Otsuka, Lundbeck eye Alzheimer's indication in FDA adcomm for Rexulti label expansion
Endpoints
Thu, 03/30/23 - 10:02 am
Otsuka
Lundbeck
Alzheimer's disease
FDA
Rexulti
Alzheimer's disease agitation
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Wed, 03/1/23 - 10:05 am
Alzheimer's disease
Biogen
Eisai
Lundbeck
Otsuka
Avanir Pharmaceuticals
Axesome
Aduhelm
Leqembi
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
Sun, 01/29/23 - 01:31 pm
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
The Top New York Biopharma Companies Hiring Now
BioSpace
Mon, 01/9/23 - 10:58 pm
New York
hirings
Regeneron
Lundbeck
Schrödinger

Pages